This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: E79.1 (Lesch-Nyhan syndrome) | Special Copayment Reduction: V221 |
| B. Synonyms | Hypoxanthine-guanine phosphoribosyltransferase (HPRT) deficiency, HPRT1 deficiency, hyperuricemia neurological disorder, Lesch-Nyhan disease (LND) |
| C. Adult onset | Likelihood of first onset in adulthood very low — classic Lesch-Nyhan syndrome begins in infancy within the first few months of life with hypotonia and developmental delay, while the mild variant of partial HPRT deficiency (Kelley-Seegmiller syndrome) may first be discovered in adulthood as gout or urolithiasis. |
| 1. History | First described by Lesch and Nyhan in 1964; HPRT deficiency identified by Seegmiller in 1967 |
| 2. Causes | HPRT (hypoxanthine-guanine phosphoribosyltransferase) deficiency due to HPRT1 gene variants → loss of the purine salvage pathway → uric acid overproduction |
| 3. Genetics | X-linked recessive; HPRT1 (Xq26.2-q26.3); almost all patients are male |
| 4. Epidemiology | About 1 per 380,000 male births; several hundred families registered worldwide |
| 5. Pathophysiology | Loss of the purine salvage pathway → inability to reuse hypoxanthine/guanine → excessive de novo purine synthesis → uric acid overproduction + dopaminergic system dysfunction |
| 6. Symptoms | Self-injurious behavior (biting lips and fingers), developmental delay, hyperuricemia, gout, urolithiasis, intellectual disability |
| 7. Signs | Choreoathetosis, dystonia, dysarthria, dysphagia, uric acid nephropathy, nodules (tophi) |
| 8. Screening | Serum uric acid measurement (confirming elevation); urine uric acid/creatinine ratio; HPRT enzyme activity measurement |
| 9. Diagnosis | HPRT enzyme activity in erythrocytes or fibroblasts; HPRT1 molecular genetic testing; prenatal diagnosis possible |
| 10. Treatment | Allopurinol (uric acid lowering), management of self-injurious behavior (behavioral therapy + restraints + medication), dopaminergic drugs; gene therapy under investigation |
| 11. Prognosis | Self-injurious behavior difficult to control; uric acid-related complications controllable with allopurinol; shortened life expectancy |
| 12. Prevention | Carrier female screening; prenatal/preimplantation genetic diagnosis; family genetic counseling |
| 13. References | List of key PMIDs and DOIs |
Lesch-Nyhan Syndrome (LNS) became known in 1964 when the American medical student Michael Lesch and his mentor William L. Nyhan first described the clinical cases of two brothers with self-injurious behavior and hyperuricemia. This landmark paper is of great significance in medical history for defining a unique combined neurological and metabolic phenotype as a single syndrome. In 1967, Seegmiller, Rosenbloom, and Kelly discovered that patients with this syndrome have a complete deficiency of the activity of hypoxanthine-guanine phosphoribosyltransferase (HPRT, Hypoxanthine-Guanine Phosphoribosyltransferase), the key enzyme of the purine salvage pathway. Subsequently, molecular biological research advanced rapidly, including development of animal models and cloning and sequencing of the HPRT1 gene. In the 1980s, a mild variant of partial HPRT deficiency presenting only with gout and urolithiasis (Kelley-Seegmiller syndrome) was described separately. Since the 2000s, from a neurobehavioral perspective, the neurobiological mechanisms of self-injurious behavior—namely, the role of basal ganglia and dopaminergic system dysfunction—have been studied intensively. In Korea, it is listed for Special Copayment Reduction as V221.
The cause of Lesch-Nyhan syndrome is complete loss of function of the HPRT enzyme due to pathogenic variants of the HPRT1 gene located on the X chromosome. In the purine salvage pathway, HPRT catalyzes the conversion of hypoxanthine and guanine to inosine monophosphate (IMP) and guanosine monophosphate (GMP), respectively. When this enzyme is deficient, the purine salvage pathway is blocked, and hypoxanthine and guanine excessively stimulate the de novo synthesis pathway that newly synthesizes purines. As a result, the overproduced purines are oxidized and converted to uric acid, and blood and urine uric acid levels rise markedly. When uric acid crystals deposit in joints, gout develops, and when they deposit in the kidneys, they cause urolithiasis and nephropathy. The mechanism of the neurological abnormalities, especially self-injurious behavior, has not been fully elucidated, but it is closely associated with reduced synthesis of the neurotransmitter dopamine in the basal ganglia. HPRT is presumed to play an essential role in the normal development and function of the dopaminergic system in the brain.
Lesch-Nyhan syndrome follows an X-linked recessive mode of inheritance. The HPRT1 gene is located on chromosome Xq26.2-q26.3 and consists of 9 exons. Because of its X-linked recessive nature, almost all patients are male (46,XY). Carrier females (heterozygotes) generally have no clinical symptoms, but when skewed X-inactivation occurs, they may show mild symptoms or, rarely, gout. Mutation types are highly diverse, including point mutations (missense, nonsense), small deletions/insertions, splice variants, and large structural variants. About 30% of all variants arise as de novo mutations, and the absence of a family history is not uncommon. The clinical phenotype is determined by the degree of residual HPRT enzyme activity. Complete deficiency (HPRT activity 0%) produces classic LNS, partial deficiency (activity 0~8%) produces Kelley-Seegmiller syndrome with only gout and no neurological abnormalities, and intermediate activity (8 to under 60%) produces phenotypes in between.
The incidence of Lesch-Nyhan syndrome is reported as about 1 per 380,000 male births, which is very rare even among X-linked recessive genetic diseases. The number of registered patients worldwide amounts to only several hundred families. Because it is X-linked recessive, female patients are extremely rare, and when one occurs, chromosomal abnormalities (45,XO, etc.) should be excluded. Differences in prevalence in specific ethnic groups or regions have not been clearly established, but carrier frequency may be higher in populations where consanguineous marriage is common. Accurate epidemiological data for Asia, including Korea, are limited. If mild variants (Kelley-Seegmiller syndrome) are included in addition to classic LNS, the actual number of patients with HPRT deficiency is larger, but these patients are often managed under other diagnoses in gout clinics and elsewhere, so registration is low.
The pathogenesis of Lesch-Nyhan syndrome due to HPRT deficiency is explained by two main pathways.
Uric acid overproduction pathway: because of the loss of the purine salvage pathway, hypoxanthine and guanine cannot be reused and fail to suppress the consumption of PRPP (phosphoribosyl pyrophosphate), so de novo purine synthesis is markedly increased. The excess synthesized purines are ultimately oxidized to uric acid by xanthine oxidase. As a result, serum uric acid reaches 2~4 times normal (10~20 mg/dL), and uric acid crystals deposit in joints (gout), kidneys (urinary stones, nephropathy), and soft tissues (tophi).
Dopaminergic system dysfunction pathway: HPRT is essential for the purine salvage pathway of basal ganglia dopaminergic neurons during brain development. Because of HPRT deficiency, normal differentiation and synapse formation of the developing striatal dopaminergic system are impaired, and striatal dopamine (especially D1 receptor) transmission is markedly reduced. This dopamine deficiency is understood to be the neurological basis of dystonia, choreoathetosis, and compulsive self-injurious behavior. The serotonin and adenosine systems are also presumed to be partly involved.
Self-injurious behavior (SIB): the most characteristic and clinically most problematic symptom of classic LNS; peculiar, compulsive self-injurious behaviors such as biting the lips, tongue, and fingers, head banging, and eye poking appear from 2~3 years of age. Patients are aware of the self-injury and do not want it, and some report that they cannot suppress the urge. They may also show aggressive behavior toward others.
Neurological symptoms: beginning with hypotonia in infancy, choreoathetosis, dystonia, and spasticity gradually appear. Dysarthria and dysphagia are prominent, accompanied by difficulty with vocalization. Walking is often impossible, and most patients depend on a wheelchair.
Metabolic symptoms: if untreated, gout (arthritis, tophi), urolithiasis, and renal dysfunction due to hyperuricemia develop. Renal failure is one of the main causes of death.
Cognitive function: mild to moderate intellectual disability occurs, but some patients retain substantial cognitive function.
The main signs found on physical examination and testing are as follows.
Choreoathetosis: involuntary, irregular limb movements are observed, interfering with the performance of purposeful movements. Accompanying dystonia is common.
Dysarthria and dysphagia: involuntary oral muscle movements due to basal ganglia dysfunction make speech unclear and food intake difficult.
Signs of self-injury: wounds, scars, and tissue loss due to repeated self-injury are observed on the lips, fingers, and elbows.
Joint findings: joint redness, swelling, and tenderness due to gout; chronic tophus formation appears in patients with delayed treatment.
Renal findings: orange stones in the kidneys due to uric acid crystals, hematuria, and findings of reduced renal function are identified.
Blood test abnormalities: markedly elevated serum uric acid (10~20 mg/dL), increased urine uric acid/creatinine ratio, absent or markedly reduced HPRT enzyme activity.
Standard newborn screening for Lesch-Nyhan syndrome is not currently performed, but the following tests are useful for early screening of clinically suspected patients. Serum uric acid measurement is the simplest screening tool; LNS should be suspected when marked hyperuricemia of 10 mg/dL or higher, 2~4 times that of normal children, is observed. The urine uric acid/creatinine ratio (above the normal age-specific reference) is also a simple screening marker. Blood test panels measuring the HPRT/APRT enzyme activity ratio are performed at some specialized institutions. When self-injurious behavior is observed in a boy with X-linked neurodevelopmental delay, uric acid measurement and specialist referral are needed immediately. In newborns from high-risk families (confirmed pedigrees), early diagnosis is possible by measuring HPRT enzyme activity early in life.
Enzyme activity measurement: the key to diagnosis is measuring HPRT enzyme activity in washed red blood cells (Washed RBC) or cultured skin fibroblasts and confirming a marked reduction compared with normal (0~1.5%). Measurement of the HPRT/APRT activity ratio using radioisotope or fluorescent substrate methods is the standard. Whole blood or plasma is not appropriate; erythrocytes or cell cultures must be used.
Molecular genetic testing: sequencing of all exons of the HPRT1 gene and exon deletion/duplication testing (MLPA) are performed. Identified variants are compared against databases such as ClinVar to assess pathogenicity.
Prenatal diagnosis: prenatal diagnosis is possible by measuring HPRT enzyme activity or analyzing the HPRT1 gene in chorionic villus samples (10~13 weeks of pregnancy) or amniotic fluid cells. For identifying carrier females, molecular genetic testing is more reliable than enzyme testing (which varies around 50% activity due to X-inactivation).
Brain MRI: abnormal development of the striatum and basal ganglia and diffuse cerebral atrophy may be observed, which helps in differential diagnosis.
Uric acid-lowering treatment: allopurinol, a xanthine oxidase inhibitor, reduces uric acid production to prevent and treat gout, urolithiasis, and renal complications. Lifelong use from early in life is required, and with treatment serum uric acid can be normalized. However, allopurinol has little effect on neurological symptoms or self-injurious behavior.
Management of self-injurious behavior: to date, there is no drug treatment that completely stops self-injurious behavior. Physical restraints (elbow immobilizers, tooth guards, gloves) are the main means of preventing physical injury from self-harm. Antipsychotic drugs such as risperidone and haloperidol reduce self-injurious urges in some patients, and baclofen (relief of dystonia), benzodiazepines, S-adenosylmethionine, and others are used. Behavioral therapy and applied behavior analysis are also used adjunctively.
Symptom management: patients with dysphagia need tube feeding (including PEG), physical therapy, occupational therapy, speech therapy, and special education support. Renal damage is prevented by monitoring renal function and ensuring adequate fluid intake. Gene therapy and stem cell-based approaches are at the research stage.
There is currently no curative treatment for Lesch-Nyhan syndrome, so the overall prognosis is poor. Self-injurious behavior is the most difficult clinical problem to manage, causing extreme stress for family and caregivers and seriously reducing the patient's quality of life. With allopurinol treatment, uric acid-related complications (gout, urinary stones, renal failure) have become largely preventable and treatable, and this is contributing to prolonged life expectancy. Neurological symptoms are non-progressive but often do not improve, and some appear to progress slowly. In the past, renal failure was the main cause of death, but with the spread of allopurinol treatment, deaths from renal complications have decreased. Currently, complications related to neurological disability, such as aspiration pneumonia and respiratory complications, are the main causes of death. Life expectancy has been extended compared with before the introduction of allopurinol, and an increasing number of patients now survive into their 30s~40s, but it is markedly shortened compared with the general population.
Lesch-Nyhan syndrome is an X-linked recessive genetic disease, and the key to prevention is early identification of carrier females and genetic counseling. A carrier female with an HPRT1 variant, in each pregnancy, has a 50% chance of having a carrier daughter and a 50% chance of having an affected son. Identification of carrier females is performed by HPRT1 molecular genetic testing. Prenatal diagnosis is possible by HPRT1 gene testing using chorionic villus samples or amniotic fluid cells, and is performed selectively in male fetuses after sex determination. Preimplantation genetic diagnosis (PGT-M) to selectively transfer only unaffected embryos is also possible. In confirmed pedigrees, early newborn testing for diagnosis before symptom onset and immediate start of allopurinol treatment can prevent renal complications. The effect of neonatal intervention for preventing neurological complications has not yet been established.